痰与血嗜酸性粒细胞浓度与COPD严重程度临床指标的关联:SPIROMICS队列分析
结果显示高痰嗜酸性粒细胞组FEV1占预计值百分比更低、肺气肿和气体陷闭的QCT指标更高、需激素治疗的急性加重更常见;
要点
- 血嗜酸性粒细胞(≥200 cells/μL)仅与轻度气道壁增厚和症状评分相关,与急性加重无关。
核心结论
- 在广泛COPD严重程度的吸烟人群中,高痰嗜酸性粒细胞比高血嗜酸性粒细胞更能识别出疾病更重、急性加重更频繁和QCT肺气肿更明显的亚组。
- 血嗜酸性粒细胞单独不能作为COPD严重程度、急性加重或痰嗜酸性粒细胞的可靠生物标志物。
- 针对COPD嗜酸性炎症的临床试验应考虑评估痰嗜酸性粒细胞。
研究设计与样本
- 多中心观察性研究,分析SPIROMICS基线数据,纳入40-80岁、吸烟史至少20包年、来自美国六个临床站点及附加站点的COPD患者。
- 研究注册号ClinicalTrials.gov NCT01969344。
主要发现
- 高痰嗜酸性粒细胞组的QCT肺气肿和气体陷闭密度指标显著高于低痰嗜酸性粒细胞组。
临床怎么用
- 血嗜酸性粒细胞计数不宜单独用于判断COPD严重程度、预测急性加重或替代痰嗜酸性粒细胞检测。
- 设计针对COPD嗜酸性炎症的临床试验时,应考虑将痰嗜酸性粒细胞作为评估指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Increased concentrations of eosinophils in blood and sputum in chronic obstructive pulmonary disease (COPD) have been associated with increased frequency of exacerbations, reduced lung function, and corticosteroid responsiveness. We aimed to assess whether high eosinophil concentrations in either sputum or blood are associated with a severe COPD phenotype, including greater exacerbation frequency, and whether blood eosinophils are predictive of sputum eosinophils. METHODS: We did a multicentre observational study analysing comprehensive baseline data from SPIROMICS in patients with COPD aged 40-80 years who had a smoking history of at least 20 pack-years, recruited from six clinical sites and additional subsites in the USA between Nov 12, 2010, and April 21, 2015. Inclusion criteria for this analysis were SPIROMICS baseline visit data with complete blood cell counts and, in a subset, acceptable sputum counts. We stratified patients on the basis of blood and sputum eosinophil concentrations and compared their demographic characteristics, as well as results from questionnaires, clinical assessments, and quantitative CT (QCT). We also analysed whether blood eosinophil concentrations reliably predicted sputum eosinophil concentrations. This study is registered with ClinicalTrials.gov (NCT01969344). FINDINGS: Of the 2737 patients recruited to SPIROMICS, 2499 patients were smokers and had available blood counts, and so were stratified by mean blood eosinophil count: 1262 patients with low (<200 cells per μL) and 1237 with high (≥200 cells per μL) blood eosinophil counts. 827 patients were eligible for stratification by mean sputum eosinophil percentage: 656 with low (<1·25%) and 171 with high (≥1·25%) sputum eosinophil percentages. The high sputum eosinophil group had significantly lower median FEV1 percentage predicted than the low sputum eosinophil group both before (65·7% [IQR 51·8-81·3] vs 75·7% [59·3-90·2], p<0·0001) and after (77·3% [63·1-88·5] vs 82·9% [67·8-95·9], p=0·001) bronchodilation. QCT density measures for emphysema and air trapping were significantly higher in the high sputum eosinophil group than the low sputum eosinophil group. Exacerbations requiring corticosteroids treatment were more common in the high versus low sputum eosinophil group (p=0·002). FEV1 percentage predicted was significantly different between low and high blood eosinophil groups, but differences were less than those observed between the sputum groups. The high blood eosinophil group had slightly increased airway wall thickness (0·02 mm difference, p=0·032), higher St George Respiratory Questionnaire symptom scores (p=0·037), and increased wheezing (p=0·018), but no evidence of an association with COPD exacerbations (p=0·35) or the other indices of COPD severity, such as emphysema measured by CT density, COPD assessment test scores, Body-mass index, airflow Obstruction, Dyspnea, and Exercise index, or Global Initiative for Chronic Obstructive Lung Disease stage. Blood eosinophil counts showed a weak but significant association with sputum eosinophil counts (receiver operating characteristic area under the curve of 0·64, p<0·0001), but with a high false-discovery rate of 72%. INTERPRETATION: In a large, well characterised cohort of former and current smoking patients with a broad range of COPD severity, high concentrations of sputum eosinophils were a better biomarker than high concentrations of blood eosinophils to identify a patient subgroup with more severe disease, more frequent exacerbations, and increased emphysema by QCT. Blood eosinophils alone were not a reliable biomarker for COPD severity or exacerbations, or for sputum eosinophils. Clinical trials targeting eosinophilic inflammation in COPD should consider assessing sputum eosinophils. FUNDING: National Institutes of Health, and National Heart, Lung, and Blood Institute.
引用
- Hastie AT, Martinez FJ, Curtis JL, et al. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017. PMID: 29146301. doi:10.1016/S2213-2600(17)30432-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。